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Abstract Secretory phospholipase A2 (PLA2) is a ubiquitous
water-soluble enzyme found in venom, pancreatic, and cancerous
£uid. It is also known to play a role in membrane remodeling
processes as well as in cellular signaling cascades. PLA2 is
interfacially active and functions mainly on organized types of
substrate, e.g. micelles and lipid bilayers. Hence the activity of
the enzyme is modulated by the lateral organization and the
physical properties of the substrate, in particular the structure
in the nanometer range. The evidence for nano-scale structure
and lipid domains in bilayers is brie£y reviewed. Results ob-
tained from a variety of experimental and theoretical studies
of PLA2 activity on lipid-bilayer substrates are then presented
which provide insight into the biophysical mechanisms of PLA2
activation on lipid bilayers and liposomes of di¡erent composi-
tion. The insight into these mechanisms has been used to pro-
pose a novel principle for liposomal drug targeting, release, and
absorption triggered by secretory PLA2.
* 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Secretory phospholipase A2 (PLA2) refers a large class of
interfacially active enzymes that catalyze the hydrolysis of
glycerophospholipids in the sn-2 position, leading to the for-
mation of lysolipids and fatty acids [1,2]. Since there is a
substantial structural similarity between di¡erent secretory
PLA2s it is surmised that they have a common catalytic mech-
anism. PLA2 is only weakly active at monomeric substrate
but very active on organized types of substrate, e.g. micelles
or bilayers, and it is therefore not surprising that the enzyme’s
activity and mode of action to a certain extent are controlled
by the physical properties of the substrate [3^5].
Results obtained from a variety of experimental and theo-
retical studies of PLA2 activity on lipid-bilayer substrates
have provided insight into the dependence of the enzyme ac-
tivity on bilayer composition, lateral structure, and thermody-
namic conditions. The enzyme activity is often measured via
its peculiar lag-burst kinetics in terms of the lag time. In
particular, it has been studied how the lag time and the degree
of hydrolysis can be varied by changing the physical proper-
ties of the substrate [4,5].
There is accumulating evidence that small-scale structure
and lipid domains persist in lipid bilayers in the nanometer
range [6^8]. Furthermore, it has been found that PLA2 activ-
ity is sensitive to this small-scale structure, which can be var-
ied systematically by varying acyl-chain length of the phos-
pholipids, temperature, and lipid composition [3,8^12]. It has
been discovered that PLA2 activity is enhanced at polymer-
covered Stealth liposomes [13]. Detailed and systematic stud-
ies have assessed the e¡ects of polymer coverage and polymer
length, liposome surface charge, and lipid composition [14,15].
Furthermore, signi¢cant enhancer e¡ects of the hydrolysis
products on drug release have been observed [16].
In the present Minireview we report on recent progress in
the ¢eld with focus on work that has been carried out in the
authors’ own laboratory. First, we describe the present theo-
retical and experimental evidence for nano-scale structure and
lipid domains in bilayers. Second, results obtained from a
variety of experimental and theoretical studies of PLA2 activ-
ity on lipid-bilayer substrates are presented which provide in-
sight into the biophysical mechanisms of PLA2 activation on
lipid bilayers and liposomes of di¡erent composition. The
various results have been obtained from a wide range of meth-
ods and techniques, including £uorescence spectroscopy, real-
time HPLC analysis, atomic force microscopy, and molecular
modeling and computer-simulation calculations. Finally, we
describe how the insight into the biophysical mechanisms of
PLA2 recently has been used to propose a novel principle for
liposomal drug targeting, release, and absorption by secretory
PLA2 [17]. This principle takes advantage of an elevated level
of secretory PLA2 in the diseased tissue [18].
2. Lipid bilayers display small-scale structure and lipid domains
Whereas the distinct trans-bilayer structure and lateral pres-
sure pro¢le of lipid bilayers are well-established features of
membranes, the lateral organization, in particular on scales
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ranging from 10 to 1000 nm, is much less well-characterized
[19]. However, in recent years an increasing amount of indi-
rect and direct evidence from studies of model membranes as
well as biological membranes has suggested that membranes
are often laterally structured in terms of domains and so-
called rafts [20]. The length and timescales of these domains
remain controversial, and domain diameters from a few nano-
meters to many micrometers have been reported. The general
observation is that the techniques that have the higher spatial
resolution also tend to ¢nd domains of a smaller size. Lipid
domains and rafts are stabilized by a number of di¡erent
interactions, including membrane^cytoskeleton, lipid^protein,
and lipid^lipid interactions, and the organization can be both
of an equilibrium as well as a non-equilibrium nature [19].
We shall focus here on lipid-domain formation caused by
the fundamental interactions between lipid molecules and the
derived cooperative behavior that is of particular importance
for PLA2 activity in the present context. In the top panel of
Fig. 1 is shown a gallery of the lateral organization of simple
one- and two-component lipid bilayers as obtained from com-
puter-simulation calculations and atomic force microscopy. A
pronounced degree of lateral heterogeneity in terms of lipid
domains is found. The domains are caused by the lateral
density and compositional £uctuations that are associated
with the underlying phase transitions and phase equilibria in
the lipid bilayers. The lipid domains are either solid lipid
patches in £uid bilayers or £uid lipid patches in solid bilayers.
In the case of lipid mixtures, the domains may re£ect incom-
plete phase separation. The size, morphology, and topology of
the domain pattern depend on the lipid composition and the
thermodynamic conditions. The domains can be enhanced or
suppressed by adding further lipid components or solutes [21].
Similar lipid-domain patterns have been found in other lip-
id-bilayer systems using a variety of experimental techniques,
including £uorescence spectroscopy [22], £uorescence micros-
copy [23], single-particle tracking techniques [24], scattering
techniques [25], and atomic force microscopy [26,27]. In par-
ticular, direct-imaging techniques like atomic force microsco-
py applied to solid-supported bilayers and £uorescence mi-
croscopy applied to solid-supported lipid bilayers or giant
unilamellar vesicles have revealed lipid domains in the range
from tens of nanometers to micrometers, depending on the
lipid membrane in question.
3. PLA2 is sensitive to the lateral structure of lipid bilayers
Being presented to a substrate that is laterally heteroge-
neous like those shown in the top panel of Fig. 1, PLA2
has the option of binding to and hydrolyzing lipid bilayers
in very di¡erent states: the domains, the background phase,
and the domain interfaces. It is important to note that the
enzyme only senses structure and structural variations over
length scales that are smaller or comparable to the scale
over which the enzyme di¡uses within the time-frame of an
Fig. 1. Small-scale structure and domain formation in lipid bilayers (top panel) and the corresponding temperature dependence of PLA2 activ-
ity (bottom panel) measured by the inverse lag time, d31. a: DMPC; b: DPPC; c: DSPC; d: 1:1 DMPC^DSPC (courtesy of Pernille Hyrup).
The domain structures in cases a, b, and c are obtained from computer-simulation calculations (frames are 100 nmU100 nm), and in case d by
atomic force microscopy of a solid-supported bilayer (frame is 1 WmU1 Wm; courtesy of Thomas Kaasgaard). The lag-time data are obtained
for snake venom PLA2 (Agkistridon piscivorus piscivorus) from a combination of £uorescence spectroscopy, light-scattering, real-time HPLC
analysis, and pH-stat titration.
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actual hydrolytic event. Hence the enzyme does not care
about the large-scale thermodynamic behavior of the sub-
strate, but only the small-scale structure.
This is supported by the data shown in the bottom panel of
Fig. 1, which shows the inverse lag time as a function of
temperature for the same four lipid substrates as in the top
panel. For the one-component bilayers there is a dramatic
increase in activity at the phase transition temperature [3],
and for the binary mixtures there is enhanced activity at the
phase boundaries and in the phase-coexistence region [12,28].
These observations suggest that the activity of PLA2 is modu-
lated by the small-scale lateral structure of the bilayer sub-
strate. The relationship between PLA2 activity and lateral
bilayer heterogeneity can be made semi-quantitative via com-
parison with results from computer-simulation calculations
[3,9]. This comparison suggests that PLA2 may be particularly
active at domain interfaces that are sites of structural defects
and hence good points of attack for the enzyme. Similar con-
clusions have been drawn from early work on lipid mono-
layers [29].
This general picture of PLA2 activation is supported by
detailed analyses of atomic force microscopy images of sol-
id-supported bilayers in the presence of PLA2 in the various
stages before and after the lag phase [8,10,11]. These analyses
strongly suggest that PLA2 attacks at areas with structural
defects, such as at domain boundaries, at regions with accu-
mulated hydrolysis products, and at the edges of pre-existing
holes in the bilayer. This is also in line with ¢ndings suggest-
ing that PLA2 activity is enhanced on lipid vesicles of decreas-
ing size, i.e. increasing curvature [30]. In the case of bilayers
made of lipids with di¡erent chain length, it has been found
that, although the enzyme seems to bind uniformly across
solid and £uid domains enriched in the long- and short-chain
lipid species, respectively, the enzyme has a preference for the
short-lipid species which is ¢rst hydrolyzed [8,12,31]. It is
possible that the preference for the short-chain lipids, which
are in the £uid phase, is due to the lower surface area density
of the lipid head groups in this phase. This would be in line
with observations of enhanced PLA2 activity on giant unila-
mellar liposomes which are subject to an osmotic stress that
lowers the surface density [32].
4. PLA2 activity is enhanced at Stealth liposomes
Bare unilamellar liposomes are poor candidates for drug
delivery systems because the liposomes are quickly caught
and degraded by the immune system. It has been known for
some time that by covering the liposomes by an appropriate
polymer coat the liposomes become invisible to the macro-
phages and therefore enjoy long circulation times in the blood
stream. These so-called Stealth liposomes [33] contain a cer-
tain fraction of lipopolymers often of the type poly(ethylene-
glycol) (PEG) which is covalently attached to a phosphatidyl-
ethanolamine lipid head group as illustrated in Fig. 2.
It would intuitively be expected that the polymer coat
should inhibit the access of enzymes like PLA2 to the lipo-
some surface and hence lower the enzyme activity. In contrast,
it was found that the presence of the lipopolymers decreases
the lag time of PLA2 as shown in Fig. 3a [13]. Subsequent
systematic studies of the dependence of the lag time on lipo-
polymer content and polymer length suggested that the en-
hancement of PLA2 activity is an electrostatic e¡ect caused by
the attraction between the positively charged PLA2 and the
negative charges of the phosphate head groups of the lipo-
polymers [14] (cf. Fig. 2). This was con¢rmed by the ¢nding of
a suppression of activity when a methyl group is coupled to
the phosphate head group, rendering it uncharged. In this case
the screening of the enzyme from the liposome surface by the
polymer coat becomes e¡ective [15].
Stealth liposomes maintain the lipid phase transition of
lipid bilayers and are therefore subject to the same £uctua-
tions and domain-formation phenomena as described above
(see Fig. 1). This implies that the degradation of Stealth lipo-
somes can be made thermosensitive. This e¡ect is illustrated in
Fig. 2. Chemical structure of the lipopolymer DPPE^PEG2000.
Fig. 3. a: Dependence of the lag time, d, of PLA2 activation on li-
popolymer coverage of DPPC liposomes incorporated with increas-
ing amounts of DPPE^PEG750 (squares), PE^DPPEG2000 (circles),
and DPPE^PEG5000 (triangles). The numbers denote the molar
weight of the polymers, corresponding to 17, 45, and 114 monomers
of ethylene oxide units. b: Dependence of the lag time, d, of PLA2
activation in the neighborhood of the phase transition of DPPC
liposomes incorporated with increasing amounts of DPPE^PEG2000
lipopolymers (0, 2.5, and 5 mol% from top to bottom). c: Drug-re-
lease characteristics of DPPC liposomes incorporated with increas-
ing amounts of DPPE^PEG2000 lipopolymers (0, 2.5, and 5 mol%
from right to left). d: The e¡ect on calcein release from liposomes
in the presence of the hydrolysis products, lysolipids (triangles), free
fatty acids (diamonds), and equimolar amounts of lysolipids and
fatty acids (squares).
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Fig. 3b, which shows the action of PLA2 on Stealth liposomes
in the temperature region of the main phase transition.
The action of PLA2 on liposomes can be used as a mech-
anism to decrease their permeability barrier, open them up,
and possibly release molecular compounds (e.g. drugs) that
have been encapsulated in their aqueous lumen or in their
bilayer wall. This e¡ect is illustrated in Fig. 3c, in the case
of calcein, which is a self-quenching £uorescent molecule
whose release from the liposomes can be monitored by £uo-
rescence intensity measurements. The ¢gure shows that the
release of the encapsulated calcein model drug becomes faster
for increasing polymer coverage.
The zwitterionic phosphatidylcholine (PC) phospholipids
that are substrates for PLA2 are good bilayer formers. In
contrast, the hydrolysis products, free fatty acids and lysolip-
ids, are molecules that have e¡ective shapes like a cone and
an inverted cone, respectively. Hence they have propensity for
forming non-lamellar phases [34] and therefore tend to desta-
bilize lipid bilayers and lower their permeability barrier. This
e¡ect is illustrated in Fig. 3d, which shows that the calcein
release from liposomes is enhanced upon addition of either of
the two products. Moreover, a dramatic synergistic e¡ect is
observed when the two products are added simultaneously
[16]. This suggests that the permeability enhancing e¡ects of
lysolipids and free fatty acids are optimal when the two spe-
cies are introduced at the same time. Hence, PLA2 action is
an extremely convenient way of producing permeability en-
hancers at the site where they are needed.
We shall discuss below how one can take advantage of
these physico-chemical e¡ects on PLA2 activity when con-
structing smart liposome-based drug-delivery systems.
5. Triggered liposomal drug release by PLA2 in diseased tissue
One of the most important questions when administering
highly potent but also very toxic drugs is how to achieve a
targeted and localized drug delivery at the diseased target
tissue [35,36]. In particular, the clinical use of anti-cancer
drugs, which have shown promising in vitro e⁄cacy, is often
prohibited due to insu⁄cient tumor delivery and severe sys-
temic side e¡ects. Polymer-covered Stealth liposomes can be
used as promising particulate microcarriers of encapsulated
drugs to diseased sites in the body [37]. The protective e¡ect
induced by the lipopolymers against degradation by, e.g. mac-
rophages, in the vascular system is generally understood in
terms of a steric barrier induced by the £exible polymer chains
attached to the surface of the liposomes [37,38]. The long-
circulating PEG^liposomes will accumulate in pathological
tissue due to leaky capillaries [39,40]. Although PEG^lipo-
somes solve some of the important carrier problems in drug
delivery, it is still a major task to control and trigger the
degradation of the drug carrier liposomes to occur predomi-
nantly at the target site. In recent years several promising
liposomal drug-delivery strategies have appeared for site-spe-
ci¢c drug release in pathological tissues. Promising examples
include temperature sensitive liposomes and peptidase target-
ing of liposomes [35,36].
The insight into the biophysical mechanisms of PLA2 acti-
vation at lipid bilayer interfaces has recently led to the design
of a novel principle for liposomal drug targeting, release and
absorption by secretory PLA2, as illustrated in Fig. 4 [16,17].
The phospholipase hydrolyzes a lipid-based pro-drug or pro-
enhancer liposome, leading to products that in a synergistic
fashion promote liposome destabilization and drug release at
the same time that the permeability of the target membrane is
enhanced. The new liposomal drug-delivery system o¡ers a
rational way of developing smart lipid-based drug-delivery
systems by incorporating into the liposome carrier-speci¢c
lipid-based pro-enhancers, pro-destabilizers or pro-drugs,
e.g. anti-cancer ether lipids [41], that automatically become
activated by elevated concentrations of PLA2 at the diseased
target sites, such as in£amed or cancerous tissue [42^44].
6. Conclusions and perspectives
The combined theoretical and experimental studies reported
in this Minireview provide information about the many-par-
ticle behavior of the lipid bilayer that might be of relevance
for a deeper understanding of the relationship that exists be-
tween the structural and dynamical properties of lipid bilayers
and the activity of the small lipolytic PLA2 enzyme. In par-
ticular, a detailed insight into the in£uence of lipid composi-
tion on structural and functional biomaterial properties of
composite liposome systems is of relevance for a rational de-
velopment of liposomes as targeted drug-carrier systems. The
biophysical studies presented above might advantageously be
used to design and optimize the site-speci¢c in vivo degrada-
tion of drug-loaded liposomes at the desired pathological site,
which is characterized by leaky capillaries [37,39] and elevated
levels of PLA2 [42^44]. The biophysical results suggest that
long-circulating and polymer-grafted liposomes, which are
known to accumulate in diseased tissue with leaky capillaries
[39,40], can also be designed to become susceptible to PLA2-
catalyzed degradation leading to a remote and site-speci¢c
release of the encapsulated drugs speci¢cally at the diseased
target site [16,17].
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Fig. 4. Schematic principle of triggered liposomal drug release by
PLA2 in diseased tissue. Polymer-covered liposomes are known to
accumulate in diseased tissue with leaky capillaries and elevated
concentrations of PLA2. Subsequently, PLA2-catalyzed degradation
of the liposomes leads to a site-speci¢c release and absorption of
the encapsulated drugs at the diseased and desired target site.
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